Navigation Links
Kensey Nash Reports Third Quarter Record Revenue and Sales
Date:4/29/2008

ssets related to the Company's decision in June 2007 to discontinue the

embolic protection product line. Additional charges related to severance

and clinical trial closeout costs were recorded in the first fiscal

quarter of 2008, as set forth in the reconciliation. In addition, the

Company is excluding the impact of the acceleration of vesting of the

stock awards from the first quarter results due to the "Change in Control"

as defined in the Company's equity compensation plan on August 30, 2007

when Ramius Capital Group, L.L.C. and its affiliates acquired more than 20

percent of the Company's outstanding common stock.

These non-GAAP measures will provide investors and management with an

alternative method for assessing Kensey Nash's operating results in a

manner consistent with the presentation prior to the discontinuance of our

embolic protection division and the accelerated vesting of stock awards.

Further, these non-GAAP results are one of the primary indicators

management uses for planning and forecasting in future periods. The

presentation of this additional information should not be considered in

isolation or as a substitute for results prepared in accordance with

accounting principles generally accepted in the United States.


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference
2. Kensey Nash Announces $25 Million Stock Repurchase Program
3. Kensey Nash Reports Acceleration of Stock Awards Triggered by Shareholder Acquisition of Greater Than 20% of Outstanding Shares
4. Kensey Nash Reports First Quarter Fiscal Year 2008 Results
5. Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform
6. Kensey Nash to Present at the 19th Annual Piper Jaffray Health Care Conference
7. Kensey Nash Corporation Announces Its Second Quarter 2008 Earnings Release Date and Teleconference
8. Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million
9. Kensey Nash to Participate in the Sidoti Twelfth Annual New York Emerging Growth Institutional Investor Forum Conference
10. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
11. Haemacure Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2013)... June 20, 2013 Footwear etc. is pleased ... USA , and has received many new styles and colors ... models, and models never before introduced in the U.S. The ... loyal following of MBT customers. , MBT shoes feature a ... on sand. This sole also provides outstanding shock absorption, and ...
(Date:6/20/2013)... June 20, 2013 TASC, a ... announced a new service to deal with funding ... the Patient Protection & Affordable Care Act (PPACA), ... health outcomes, clinical effectiveness, and appropriateness" of different ... and conduct its own, with funding in part ...
(Date:6/20/2013)... David Icke, the highly visible alternative researcher and ... , Fresh from the Bilderburg fringe festival and the ... to launch ‘The Peoples Voice’ TV and Radio station by ... opportunity for journalists to cover the stories and investigations that ... globe. , Because this station is for the people, ...
(Date:6/20/2013)... Sydney, Australia (PRWEB) June 20, 2013 ... , research was presented recently, that can show similarities ... food. This could explain the current global obesity ... be addicted to food just as one can be ... Neuroscience and Applied Cognitive Science at the University of ...
(Date:6/20/2013)... 2013 HIPAA One aims ... through a HIPAA Security Risk Analysis using the simplest ... extends the reach of all the HIPAA programs by ... Privacy Officers, security professionals, and members of the Healthcare ... policies and procedures. The new Web site features ...
Breaking Medicine News(10 mins):Health News:Footwear etc. Announces New MBT Shoes for Spring/Summer 2Health News:TASC Service Helps Employers Handle New Burdens for Health Reimbursement Arrangement Plans 2Health News:Research Suggests That Unhealthy Food Addiction Could Explain Global Obesity Epidemic 2Health News:Modern Compliance Solutions Launches a New Web Site Promoting the Industry-Proven, Web-Based HIPAA One Security Solution 2
... - Sanofi Pasteur committed to increasing its seasonal ... production capacity in the U.S. -SWIFTWATER, Pa. and ... vaccines division of sanofi-aventis Group (EURONEXT: SAN and ... the U.S. Food and Drug Administration (FDA) has ...
... May 6 Funds in the FY 2010 budget aimed ... to improve access to outpatient physical therapy services for Medicare ... Therapy Association (APTA). S.Con.Res.13 ... 2009-FY 2014, was passed April 29 by the House of ...
... Mary Bono Mack (CA-45) and Nita Lowey (NY-18) ... and well-being of American youth by reintroducing the ... The bipartisan legislation, broadly supported by such organizations ... cross-sector collaboration for improving the health of young ...
... Team Finance LLC (the "Company"), today announced results for the ... uncollectibles ("revenue less provision") in the first quarter of 2009 ... first quarter of 2008. Same contract revenue less provision ... million in the same period a year ago. In ...
... bare-metal version, studies show , , WEDNESDAY, May 6 ... stents are less likely to become blocked again than ... and heart attacks is virtually identical between the two ... show. , The Swedish results eliminate concerns raised by ...
... of those hospitalized in U.S. is 15, CDC says , , ... of U.S. cases of swine flu continue to be mild, ... be atypically young, federal health officials said Wednesday. , The ... which is younger than occurs with regular seasonal flu, Dr. ...
Cached Medicine News:Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 2Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 3Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 4Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 5Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 6Health News:Funds in 2010 Budget Could Increase Access to Care for Medicare Beneficiaries 2Health News:Bono Mack, Lowey Introduce Bill To Improve the Health of Youth 2Health News:Team Finance LLC Announces First Quarter 2009 Results 2Health News:Team Finance LLC Announces First Quarter 2009 Results 3Health News:Team Finance LLC Announces First Quarter 2009 Results 4Health News:Team Finance LLC Announces First Quarter 2009 Results 5Health News:Team Finance LLC Announces First Quarter 2009 Results 6Health News:Team Finance LLC Announces First Quarter 2009 Results 7Health News:Team Finance LLC Announces First Quarter 2009 Results 8Health News:Drug-Coated Stents Better at Keeping Arteries Open 2Health News:Drug-Coated Stents Better at Keeping Arteries Open 3Health News:Younger Age of More Severe Swine Flu Cases Worries Experts 2Health News:Younger Age of More Severe Swine Flu Cases Worries Experts 3Health News:Younger Age of More Severe Swine Flu Cases Worries Experts 4Health News:Younger Age of More Severe Swine Flu Cases Worries Experts 5Health News:Younger Age of More Severe Swine Flu Cases Worries Experts 6Health News:Younger Age of More Severe Swine Flu Cases Worries Experts 7Health News:Younger Age of More Severe Swine Flu Cases Worries Experts 8Health News:Younger Age of More Severe Swine Flu Cases Worries Experts 9Health News:Younger Age of More Severe Swine Flu Cases Worries Experts 10Health News:Younger Age of More Severe Swine Flu Cases Worries Experts 11Health News:Younger Age of More Severe Swine Flu Cases Worries Experts 12
(Date:6/19/2013)... 19, 2013   NextDocs announced today that ... research organization, at DIA 2013 , the Drug ... present case studies that explore best practices for making ... trial master file (eTMF) systems. Sharon ... alongside Krystyna Kowalczyk , executive vice president of ...
(Date:6/19/2013)... June 19, 2013  Finesse Solutions, Inc, a ... sciences process applications, announced the launch of its ... cell culture and fermentation.  The 3L glass vessels ... of Finesse bioreactors and are designed to optimize ... are fully compatible with all Finesse G3Lab controllers, ...
(Date:6/19/2013)... , June 19, 2013 ... recently added DrugPatentWatch to its extensive ... )      (Logo: http://photos.prnewswire.com/prnh/20130128/590935) ... information on pharmaceutical, drug patents and ... the critical business functions of patent ...
Breaking Medicine Technology:NextDocs and Novella to Present on eTMF at DIA 2013 2Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2Drug Patent Watch 2Drug Patent Watch 3
... to be held on Wednesday, August 6, 2008 at 8:00 ... ... 5 Isolagen(TM), Inc. (Amex:,ILE) announced today positive top-line efficacy and safety ... the,Isolagen Therapy(TM) for the treatment of nasolabial folds, or wrinkles.,Each study, conducted ...
... WHIPPANY, N.J., Aug. 5 Nexgen Spine, a ... treatment of,degenerative disc disease, announced today that it ... Lumbar Artificial Disc in the European,Union., "We ... has,received CE mark approval," said Alastair Clemow, Ph.D., ...
Cached Medicine Technology:Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 2Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 3Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 4Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 5Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc 2
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
... The new Guidant VASOVIEW® HemoPro™ ... deliver a new level of ... for both the saphenous vein ... cut-and-seal capability, it lets you ...
Patient Monitor...
...
Medicine Products: